تنبيه هام: هذا المقال يحتوي على معلومات عامة فقط. يُرجى استشارة طبيبك قبل اتخاذ أي إجراءات صحية أو تناول أي أدوية.
Capivasertib, now approved by the National Health Service (NHS) in England and Wales, is taken twice a day as a tablet. Linda described the side effects as minimal and called the results “fantastic.” Thanks to the drug, she remains active, cycling 60 miles a week and regularly doing Pilates.
Clinical trials involving 708 women revealed that combining capivasertib with hormone therapy doubled the time before cancer progression—from 3.6 months to 7.3 months. It also reduced tumor size in 23% of the women. Professor Nick Turner, the lead researcher, highlighted the drug’s effectiveness, noting it can delay the need for chemotherapy, which many patients fear due to harsh side effects.
Currently, the drug is funded by the Cancer Drugs Fund in England, but its availability in Wales is still pending. Breast cancer is the most common cancer in the UK, affecting one in seven women. While most survive 10 years or more, treatment options remain critical when cancer returns and spreads.
Linda says the treatment has given her a renewed sense of hope: “It really makes you reflect on your life and what you want to do. But now I feel well enough to plan and confident enough to make those plans happen.”
